Targeted therapy of renal cell carcinoma
β
Stefan Bauer; Jeannette C. Oosterwijk-Wakka; Nicole Adrian; Egbert Oosterwijk; E
π
Article
π
2009
π
John Wiley and Sons
π
French
β 477 KB
## Abstract Immunotherapeutic targeting of G250/Carbonic anhydrase IX (CAβIX) represents a promising strategy for treatment of renal cell carcinoma (RCC). The well characterized humanβmouse chimeric G250 (cG250) antibody has been shown in human studies to specifically enrich in CAβIX positive tumor